Online inquiry

IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6713MR)

This product GTTS-WQ6713MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets EGFR gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Chimeric
RefSeq NM_001346897.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956
UniProt ID Q504U8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6713MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ4691MR IVTScrip™ mRNA-Anti-MAPT, BMS-986168(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-986168
GTTS-WQ5538MR IVTScrip™ mRNA-Anti-CD40LG, CDP7657(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP7657
GTTS-WQ11082MR IVTScrip™ mRNA-Anti-CSF1, MCS-110(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MCS-110
GTTS-WQ2281MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ALXN1007
GTTS-WQ8641MR IVTScrip™ mRNA-Anti-AXL, HuMax-AXL-ADC(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA HuMax-AXL-ADC
GTTS-WQ6255MR IVTScrip™ mRNA-Anti-HA, CR-6261(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CR-6261
GTTS-WQ5315MR IVTScrip™ mRNA-Anti-CD3E&MS4A1, CD20-TCB (2:1)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA CD20-TCB (2:1)
GTTS-WQ8773MR IVTScrip™ mRNA-Anti-PCSK9, IBI-306(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-306
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW